Analyst Price Target is $2.25
▲ +336.89% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Advaxis in the last 3 months. The average price target is $2.25, with a high forecast of $2.25 and a low forecast of $2.25. The average price target represents a 336.89% upside from the last price of $0.52.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Advaxis. This rating has held steady since May 2020, when it changed from a Hold consensus rating.
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.